

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 9, 2026**

---

**QUANTERIX CORPORATION**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-38319**  
(Commission File Number)

**20-8957988**  
(IRS Employer  
Identification No.)

**900 Middlesex Turnpike**  
**Billerica, MA**  
(Address of principal executive offices)

**01821**  
(Zip Code)

**(617) 301-9400**  
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class:	Trading symbol(s):	Name of each exchange on which registered:
Common Stock, \$0.001 par value per share	QTRX	The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging Growth Company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

The Board of Directors of Quanterix Corporation (the “Company”) has appointed Jason Faessler as the Chief Financial Officer and Treasurer of the Company. He is expected to commence employment with the Company on June 22, 2026.

Mr. Faessler mostly recently was employed by Brucker Corporation as Senior Vice President of Finance, leading global FP&A and the Americas finance organization. His responsibilities have included strategic planning, operational finance and capital decision-making. Before that, he was Senior Director of Finance at Parexel Corporation from April 2018 to December 2018 and Director of Finance at Parexel from November 2015 to April 2018, where he led its early- and late-phase clinical divisions, driving growth and profitability across both businesses. Prior to Parexel, Mr. Faessler worked as Director of Finance and Sales Operations at Harvard Business Publishing and held several financial planning, analysis and operation roles at EMC Corporation. Mr. Faessler earned an MBA from the F.W. Olin Graduate School of Business at Babson College and a BA from the University of Massachusetts Boston.

The Company has entered into an employment agreement dated May 31, 2026 with Mr. Faessler (the “Employment Agreement”) in connection with his appointment as Chief Financial Officer and Treasurer. The Employment Agreement provides for an initial annualized base salary of \$475,000, a cash sign-on bonus of \$200,000, and eligibility for an annual performance bonus with an annual bonus target of up to 50% of Mr. Faessler’s base salary.

In connection with his appointment, Mr. Faessler also will receive a long-term equity incentive award consisting of restricted stock units (RSUs) covering shares of the Company’s common stock, par value \$0.001 per share (the “Common Stock”), equivalent to three-tenths of one percent (0.30%) of the shares of Common Stock outstanding on his start date. The RSUs vest in four equal annual installments on each of the first four anniversaries of Mr. Faessler’s start date.

If Mr. Faessler’s employment is terminated by the Company without Cause (as defined in the Employment Agreement) or he resigns for Good Reason (as defined in the Employment Agreement), then he will receive continued payment of his base salary for 12 months (the “Severance Period”), payment of an amount equal to his annual target bonus for the year of termination, pro-rated as of the date of termination, and subsidized health benefits during the Severance Period. If Mr. Faessler’s employment is terminated by the Company without Cause or he resigns for Good Reason in connection with a Change-in-Control (as defined in the Employment Agreement), then he will receive continued payment of his base salary for 12 months, payment of an amount equal to his annual target bonus for the year of termination, subsidized health benefits during the Severance Period, and all of his outstanding but unvested equity awards will also become fully vested. Receipt of the foregoing termination benefits will be subject to Mr. Faessler’s execution of a separation agreement, including certain restrictive covenants and a general release of all claims, in a form acceptable to the Company.

A copy of the Employment Agreement is filed as Exhibit 10.1 and is incorporated herein by reference.

Except for the Employment Agreement, there are no arrangements or understandings between Mr. Faessler and any other person pursuant to which Mr. Faessler was appointed as an officer. There are no family relationships between Mr. Faessler and any director, director nominee or executive officer of the Company. There are no transactions to which the Company is a party and in which Mr. Faessler has a material interest that are required to be disclosed under Item 404(a) of Regulation S-K.

**Item 7.01 Regulation FD Disclosure.**

On June 9, 2026, the Company issued a press release, which announced the appointment of Mr. Faessler as Chief Financial Officer and Treasurer of the Company (the “Release”). A copy of the Release is attached as Exhibit 99.1 and incorporated herein by reference.

The information contained or incorporated in this Item 7.01, including Exhibit 99.1, is being furnished, and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

---

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

<b>Exhibit No.</b>	<b>Description</b>
10.1	<a href="#">Employment Agreement by and between the Company and Jason Faessler</a>
99.1	<a href="#">Press Release dated June 9, 2026</a>
104	Cover Page Interactive Data File (embedded within the inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Date: June 9, 2026

**QUANTERIX CORPORATION**

**By:** /s/ Daniel S. Char  
**Name:** Daniel S. Char  
**Title:** Chief Legal Officer and Corporate Secretary

Quanterix  
900 Middlesex Turnpike | Building 1  
Billerica, MA 01821

Jason Faessler  
Delivered via Email

Re: **Employment Agreement**

Dear Jason:

Quanterix Corporation (the "Company") is pleased to offer you the full-time, exempt position of Chief Financial Officer, reporting to Everett Cunningham, Chief Executive Officer. Your start date will be June 22, 2026. This role is required to be in our Billerica, MA office.

Congratulations on this offer and career opportunity with Quanterix!

1. **Base Salary:** The Company will pay you a salary at an annual rate of \$475,000.00, paid at a bi-weekly rate of \$18,269.23 (less all applicable taxes and deductions), subject to periodic review and adjustment at the discretion of the Company.
2. **Annual Bonus:** Your bonus target is 50% of your annual base salary. You will be eligible to participate in the 2027 bonus program; bonus amounts may be pro-rated bonus based on your start date. The actual bonus award amount is subject to the Company's assessment of your individual performance, as well as existing business conditions of the Company. In order to receive the annual bonus, you must be actively employed on the date the bonus is paid. All bonuses are paid at the discretion of the Company and Company's Board of Directors and are subject to the terms of any applicable bonus plan.
3. **Benefits:** You will be eligible to participate in the employee benefits and insurance programs generally made available to its full-time employees, including medical insurance, dental insurance, 401K plan, flexible Spending Account, term life insurance, and short- and long- term disability insurance. Details of these benefits programs, including mandatory employee contributions, will be made available to you when you start. You will also be eligible to participate under the company's Paid Time Off plan. Details of the policy and specific provisions are set forth in the policy itself.
4. **Sign on Equity Award:** You will be eligible to receive a sign-on equity award. The company will target an equity award up to 0.30% Common Shares Outstanding (CSO) on a fully diluted basis determined as of the grant date. Based on the Company's capitalization from the prior quarter close this award is expected to be approximately 140k restricted stock units (RSUs), however, the final number of shares may vary based on the Company's capitalization as of the grant date. Equity awards are granted on an approximately monthly basis, and we will submit your award for approval as soon as administratively practicable, generally within 30 to 45 days after your start date. Your equity award will vest over four (4) years, with 25% vesting on the first anniversary of the grant date and the remaining 75% vesting in three (3) equal annual installments, thereafter, rounded down to the nearest whole share. All equity awards are subject to the terms and conditions of the Company's 2017 Employee, Director and Consultant Equity Incentive Plan and the applicable award agreement(s).
5. **Sign on Cash Award:** In addition, Quanterix will grant you a one-time bonus of \$200,000 (less all applicable taxes and deductions), payable in the first payroll cycle following 30 days of employment. If you voluntarily separate your employment with Quanterix prior to the first-year anniversary of your start date, you will be expected to return the full gross amount of your sign-on bonus. Repayment of the full gross amount will be due to Quanterix with-in thirty (30) days of your last day of employment.

6. **Long-Term Equity Incentive:** You will be eligible to receive annual equity awards beginning in 2027. Your equity award may consist of stock options and restricted stock units (RSUs) and will be determined using the Company's standard valuation methodology as of the date your award is approved. Your equity award will vest over a four-year vesting schedule with annual vesting. Your award will also be subject to the terms of our 2017 Employee, Director and Consultant Equity Incentive Plan and the applicable award agreements.

7. **At-Will Employment: Accrued Obligations:** Your employment is "at will," meaning you or the Company may terminate your employment at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the "Accrued Obligations," defined as (1) your base salary through the date of termination; (2) the amount of any expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed; and (3) to the extent not theretofore paid or provided, any other amounts or benefits required to be paid or provided or which you have earned under any plan or agreement of or with the Company through the date of termination.

8. **Severance:** Without limiting the at-will nature of your employment relationship, if Quanterix Corporation (the "Company") terminates your employment without Cause, or if you resign for Good Reason, the Company shall provide you with the following termination benefits (the "Termination Benefits").

- (a) **Salary Continuation Payments.** Continuation of your base salary for a period of twelve (12) months after the date of termination (the "Severance Period") at the salary rate then in effect.
- (b) **Target Bonus.** An amount equal to your annual target bonus for the year of termination, pro-rated as of the date of termination and paid in one lump sum on the Company's next regularly scheduled payroll date following the effective date of the separation agreement described below.
- (c) **Health Benefits Continuation.** Continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. § 1161 et seq. (commonly known as "COBRA"), with the cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of (i) the end of the Severance Period; or (ii) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA ("Health Benefits Continuation Payments"). Notwithstanding the above, (x) in the event that the Severance Period extends beyond eighteen (18) months following your date of termination, or (y) if the Company otherwise determines in its sole discretion that it cannot provide the foregoing Health Benefits Continuation Payments without potentially violating applicable law (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the Company's portion of the monthly COBRA premium (as described above) that you would be required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether COBRA continuation coverage remains available (i.e., in the event that the Severance Period extends beyond eighteen (18) months following your date of termination) and shall end on the earlier of (1) the end of the Severance Period, (2) the date you become eligible for health benefits through another employer or otherwise become ineligible for COBRA; or (3) the last day of the twenty-fourth (24th) calendar month following your termination date.

If the Company terminates your employment without Cause, or if you resign for Good Reason, and the effective date of such termination occurs within the 90 day period immediately preceding or the twelve (12) month period immediately following a Change- in-Control (such period the "Change-in-Control Period" and such termination a "Change-in- Control Termination"), then the Termination Benefits shall be as follows:

- (v) The Severance Period as defined in (a) above shall be a period of twelve (12) months after the date of termination.

- (w) Your Health Benefits Continuation shall be as provided in (c) above for the Severance Period defined in (v) immediately above.
- (x) An amount equal to your annual target bonus for the year of termination, paid in one lump sum on the Company's next regularly scheduled payroll date following the effective date of the separation agreement described below.
- (y) Notwithstanding anything to the contrary in any applicable equity plan or award agreement, all of your outstanding but unvested equity awards shall accelerate and become fully-vested and exercisable as of the later of (A) the termination date, (B) the effective date of the separation agreement described below, or (C) as of the Change-in-Control.
- (z) The Termination Benefits provided in connection with Change-in-Control Termination pursuant to paragraphs (v), (w), (x) and (y) above shall be in lieu of, and not in addition to, the amounts referenced in paragraphs (a), (b) and (c) above.

Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless (a) within 60 days of your date of termination, you first (i) enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company, which shall include a general release in favor of the Company and related persons and entities, and other provisions regarding non-competition, confidentiality, cooperation, non-disparagement and the like as may be included in the Company's then current form of separation agreement (the "Release"); (ii) resign from any and all positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii) return all Company property and comply with any instructions related to deleting and purging duplicates of such Company property, and (b) you comply with the terms of your confidentiality and restrictive covenants agreement or any other similar agreements with the Company. The Salary Continuation Payments shall commence within 60 days after the date of termination and shall be made on the Company's regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to be paid in the second calendar year. In the event you miss a regular payroll period between the date of termination and the first Salary Continuation Payment, the first Salary Continuation Payment shall include a "catch up" payment.

For purposes of this Section:

"Cause" means the occurrence of any of the following (and, if applicable, that the Company has complied with the Cause Process (hereinafter defined) following the occurrence of a circumstance subject to the Cause Process): (i) theft, fraud, embezzlement, misappropriation of assets or property of the Company, or material violation of your confidentiality and restrictive covenants agreement with the Company; (ii) dishonesty, gross negligence, misconduct, neglect of duties, or breach of fiduciary duty to the Company; (iii) violation of federal or state securities laws; (iv) breach of an employment, consulting or other agreement with the Company; (v) the conviction of a felony, or any crime involving moral turpitude, including a plea of guilty or *nolo contendere*; or (vi) continued, willful and deliberate non-performance by you of your duties hereunder (other than by reason of your physical or mental illness, incapacity or disability).

"Cause Process" means that (1) the Company has reasonably determined in good faith that a "Cause" condition has occurred; (2) the Company has notified you in writing of the first occurrence of the Cause condition within 60 days of the first occurrence of such condition; (3) you are provided a period of 30 days following such notice (the "Cause Cure Period") to remedy the condition; (4) notwithstanding such efforts, the Company reasonably and in good faith determines at the end of the Cause Cure Period that the Cause condition continues to exist; and (5) the Company terminates your employment within 30 days after the end of the Cause Cure Period. If you cure the Cause condition during the Cause Cure Period, Cause shall be deemed not to have occurred. The Company shall not be required to follow the Cause Process as to those conditions which it reasonably determines in good faith cannot be cured within the Cause Cure Period. For the avoidance of doubt, you and the Company acknowledge and agree that clauses (i), (iii) and (v) cannot be cured and shall not be subject to the requirements of the Cause Process.

"Change-in-Control" means the occurrence of any of the following events: (i) any "Person" (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended) becomes the "Beneficial Owner" (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Company representing fifty percent

(50%) or more of the total voting power represented by the Company's then outstanding voting securities; (ii) a change in the composition of the Company's Board of Directors occurring within a two-year period, as a result of which fewer than a majority of the directors are Incumbent Directors where "Incumbent Directors" means directors who either (A) are directors of the Company as of the date hereof, or (B) are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors at the time of such election or nomination (but will not include an individual whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company); (iii) the consummation of a merger or consolidation of the Company, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or the parent of such corporation) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or parent of such corporation, as the case may be, outstanding immediately after such merger or consolidation; or (iv) the consummation of the sale or disposition by the Company of all or substantially all of the Company's assets.

"Good Reason" means that you have complied with the Good Reason Process following the occurrence of any of the following actions undertaken by the Company without your express prior written consent: (i) the material diminution in your authority, duties and responsibilities; (ii) a material reduction in your base salary, provided, however, that Good Reason shall not be deemed to have occurred in the event of a reduction in your base salary that is pursuant to a salary reduction program affecting all or a material portion of the similarly situated senior executive level employees of the Company and that does not adversely affect you to a greater extent than such similarly situated employees; and (iii) a change in the geographic location at which you must regularly report to work and perform services of more than thirty (30) miles, except for required travel on the Company's business; or (iv) a material breach by the Company of any of its obligations to you under its employment agreements with you.

"Good Reason Process" means that (1) you have reasonably determined in good faith that a "Good Reason" condition has occurred; (2) you have notified the Company in writing of the first occurrence of the Good Reason condition within 30 days of the first occurrence of such condition; (3) the Company is provided with a period of 30 days following such notice (the "Cure Period") to remedy the condition; (4) notwithstanding such efforts, you reasonably and in good faith determine at the end of the Cure Period that the Good Reason condition continues to exist; and (5) you terminate your employment within 30 days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have occurred.

1. **Section 280G:**

- (a) If any payment or benefit you would receive under this Agreement, when combined with any other payment or benefit you receive pursuant to a Change-in-Control (for purposes of this Section 2, a "Payment") would constitute a "parachute payment" within the meaning of Section 280G of the Internal Revenue Code of 1986, as amended (the "Code") and, but for this sentence, be subject to the excise tax imposed by Code Section 4999 (the "Excise Tax"), then such Payment shall be either: (i) the full amount of such Payment; or (ii) such lesser amount (a "Reduced Payment") as would result in no portion of the Payment being subject to the Excise Tax, whichever of the foregoing amounts, taking into account the applicable federal, state and local employment taxes, income taxes and the Excise Tax, results in your receipt, on an after-tax basis, of the greater amount of the Payment notwithstanding that all or some portion of the Payment may be subject to the Excise Tax.
- (b) With respect to Section 2(a), if there is more than one method of reducing the Reduced Payment amount that would result in no portion of the Payment being subject to the Excise Tax, then the Payment shall be reduced or eliminated in the following order: (i) cash payments; (ii) taxable benefits; (iii) nontaxable benefits; and (iv) accelerated vesting of equity awards in a manner that maximizes the amount to be received by you.
- (c) The determination of whether Section 2(a)(i) or (ii) applies, and the calculation of the amount of the Reduced Payment if applicable, shall be performed by a nationally recognized certified public accounting firm as may be designated by the Company (the "Accounting Firm"). The Accounting Firm shall provide detailed supporting calculations to both the Company and you within fifteen

(15) business days of the receipt of notice from you that there has been a Payment, or such earlier time as is requested by the Company, in a form that can be relied upon for tax filing purposes. All fees and expenses of the Accounting Firm shall be borne solely by the Company.

- (d) You may receive a Payment that is, in the aggregate, either more or less than the amount described in Section 2(a)(i) or (ii) (as applicable, an "Overpayment" or "Underpayment"). If it is finally determined by a court of competent jurisdiction pursuant to a final non-appealable judgment, or the Internal Revenue Service, or by the Accounting Firm upon request by either the Company or you, that an Overpayment or Underpayment has been made, then: (i) in the event of an Overpayment, you shall promptly repay the Overpayment to the Company, together with interest on the Overpayment at the applicable federal rate from the date of your receipt of such Overpayment until the date of such repayment; and (ii) in the event of an Underpayment, the Company shall promptly pay an amount equal to the Underpayment to you, together with interest on such amount at the applicable federal rate from the date such amount would have been paid to you had the provisions of Section 2(a)(ii) not been applied until the date of payment.

9. **Section 409A:**

- a. It is intended that payments under this Agreement are exempt from, or comply with, Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its exemption or compliance with Section 409A of the Code, the provision will be read in such a manner so that all payments hereunder are exempt from or comply with Section 409A of the Code.
- b. To the extent that any payment or benefit described in this Agreement constitutes "non-qualified deferred compensation" under Section 409A of the Code, and to the extent that such payment or benefit is payable upon your termination of employment, then such payments or benefits will be payable only upon your "separation from service." The determination of whether and when a separation from service has occurred will be made in accordance with Treasury Regulation Section 1.409A-1(h).
- c. Anything in this Agreement to the contrary notwithstanding, if, at the time of your separation from service within the meaning of Section 409A of the Code, the Company determines that you are a "specified employee" within the meaning of Section 409A(a)(2)(B)(i) of the Code, then, to the extent necessary to comply with Section 409A of the Code, any payment or benefit that you become entitled to under this Agreement on account of your separation from service will not be payable and such benefit will not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment will include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments will be payable in accordance with their original schedule.
- d. It is intended that each installment of the severance payments and benefits provided under this Agreement shall be treated as a separate "payment" for purposes of Section 409A of the Code. Neither the Company nor you shall have the right to accelerate or defer the delivery of any such payments or benefits except to the extent specifically permitted or required by Section 409A of the Code. In no event will the bonus payment described in Section 1(b) or 1(x) hereof, as applicable, be paid after March 15 of the calendar year following the calendar year in which your separation from service occurs.
- e. All in-kind benefits provided and expenses eligible for reimbursement under this Agreement will be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements will be paid as soon as administratively practicable, but in no event will any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year will not affect the in-kind benefits to be provided or the expenses eligible for

reimbursement in any other taxable year. Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.

- f. The Company makes no guarantee of any tax consequences with respect to any payment hereunder, including, without limitation, under Section 409A of the Code. The Company makes no representation or warranty and will have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section, and nothing herein shall be interpreted or construed to transfer any liability for any tax (including a tax or penalty due as a result of a failure to comply with Section 409A of the Code) from you to the Company or to any other individual or entity.

10 **No Mitigation:** In no event, except as set forth expressly in this or another agreement signed by you, shall you be obligated to seek other employment or take any other action by way of mitigation of the amounts payable to you under any of the provisions of this Agreement and, subject to the aforesaid exception, such amounts shall not be reduced whether or not you obtain other employment.

11 **Assistance with Claims:** You agree that consistent with your business and personal affairs, during and after your employment by the Company, you will assist the Company and its affiliated entities in the defense of any claims, or potential claims that may be made or are threatened to be made against any of them in any action, suit or proceeding, whether civil, criminal, administrative or investigative (a "Proceeding"), and will assist the Company and its affiliated entities in the prosecution of any claims that may be made by the Company or its affiliated entities in any Proceeding, to the extent that such claims may relate to your employment or the period of your employment by the Company. The Company agrees to reimburse you for your reasonable out-of-pocket expenses associated with such assistance, including travel expenses. Any amounts to be paid to you pursuant to this section shall be paid by the Company within no later than thirty (30) days of the date on which you provide documentation to the Company that such expenses were incurred.

12 **Non-Competition Agreement:** In consideration of the benefits contained herein and those recited in Annex A and as a condition precedent to the effectiveness of this Agreement, you agree to execute the Employee Non-Competition Agreement attached as Annex A hereto.

13 **Restrictive Covenants Agreement:** If the Company elects to enforce the agreement attached as Annex A or any other non-competition provision for which post-employment payments are required under applicable law, the Company may apply the amount of any such payment(s) to the Termination Benefits.

14 **Governing Law:** The terms of this Agreement and the resolution of any dispute as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the "Dispute") will be governed by Massachusetts law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the Commonwealth of Massachusetts in connection with any Dispute or any claim related to any Dispute, and the prevailing party shall be awarded its attorneys' fees and costs.

We are excited about the opportunity to work with you at Quanterix. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer of employment by signing below and returning a copy no later than June 5, 2026.

*[Signature Page Follows]*

Sincerely,

/s/ Everett Cunningham

Everett Cunningham  
Chief Executive Officer

Offer accepted:

/s/ Jason Faessler

Name: Jason Faessler  
Date: 5/31/2026

## **Quanterix Announces Appointment of Jason Faessler as Chief Financial Officer**

BILLERICA, Mass.—June 9, 2026-- **Quanterix Corporation (Nasdaq: QTRX)**, a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced the appointment of Jason Faessler as the Company's new Chief Financial Officer, effective June 22. Faessler brings extensive finance leadership experience and expertise in managing complex organizations in the life science tools industry, positioning him to play a pivotal role in executing Quanterix's strategic growth plans in the coming years.

"We are thrilled to welcome Jason to the Quanterix leadership team," said Everett Cunningham, Chief Executive Officer of Quanterix. "His extensive track record within life science organizations makes him the ideal leader to support our ambitious growth objectives. Jason's expertise in strategic financial and capital planning, operational excellence, and commercial support will be instrumental in advancing our mission."

Faessler joins Quanterix from Bruker Corporation, where he served as Senior Vice President, leading global FP&A and the Americas Finance organization. His responsibilities have included strategic planning, operational finance, and capital decision-making. Prior to Bruker, Faessler held senior finance leadership positions at PAREXEL, where he led its Early- and Late-Phase Clinical divisions, driving growth and profitability across both businesses. Jason also held senior financial management roles at EMC (now Dell) and Harvard Business Publishing.

"I am both excited and honored to join Quanterix at this pivotal moment in its journey," Faessler adds. "The Company is uniquely positioned for growth with two leading scientific instrument platforms and an emerging diagnostics capability. Quanterix's technology is enabling earlier disease detection and deeper insights into both research and clinical settings, helping to advance science and improve patient outcomes. I look forward to partnering with Everett and the leadership team to drive sustained value creation for our shareholders by capturing these opportunities."

### **About Quanterix**

Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa<sup>®</sup> technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With approximately 6,500 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company<sup>®</sup>, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,450 installed instruments. Together, the combined company offers a uniquely integrated platform that connects

biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at [www.quanterix.com](http://www.quanterix.com).

Media  
[media@quanterix.com](mailto:media@quanterix.com)

Investor Relations  
Joshua Young  
[ir@quanterix.com](mailto:ir@quanterix.com)